A little-known veterinary sedative is making its way into the illegal drug supply across the United States, and health authorities are sounding the alarm. Authorities detected medetomidine with increasing frequency in illicit fentanyl, prompting an extraordinary joint advisory from the Centres for Disease Control and Prevention (CDC) and the White House Office of National Drug Control Policy (ONDCP) on 2 April 2026.

The warning is notable in itself. The CDC issues Health Alert Network advisories on a near-monthly basis, but these have historically focused on infectious disease outbreaks. No previous HAN has directly addressed the illegal drug supply.

What Is Medetomidine in Fentanyl?

Medetomidine is a sedative and analgesic licensed for use in dogs. It is not approved for use in humans, though its dextro-isomer, dexmedetomidine, serves in hospital settings for procedural sedation. On the streets, it goes by several names: “rhino tranq,” “mede,” or “dex.”

The medetomidine drug threat has emerged as a direct successor to xylazine, the veterinary tranquiliser that became notorious in the fentanyl supply from around 2022 onwards. As enforcement efforts targeted xylazine, clandestine producers pivoted to alternatives. Forensic testing found racemic mixtures of medetomidine with no match to any licensed pharmaceutical product. That finding strongly suggests illegal laboratories are manufacturing the substance rather than diverting it from veterinary supplies.

Medetomidine in Fentanyl: A Sharp Rise in Numbers

The scale of the increase is stark. According to the National Forensic Laboratory Information System (NFLIS), law enforcement drug seizures recorded medetomidine 247 times in 2023. That figure jumped to 2,616 in 2024, a rise of 950%. By 2025, detections reached 8,233 cases, a further 215% year on year.

The problem clusters geographically. In 2025, medetomidine in fentanyl dominated the Northeast (52% of cases) and Midwest (31%), with the South at 17%. Western states remain largely unaffected for now.

Between July and December 2025, researchers monitoring 20 sentinel sites across the US found medetomidine in nearly 35% of opioid-positive samples. Of 995 drug product samples that tested positive for medetomidine in that period, 98% also contained fentanyl. The two substances travel together almost without exception.

The Health Risks of the Medetomidine Drug Threat

Medetomidine is a potent alpha-2 adrenergic agonist, more powerful and longer-lasting than both clonidine and xylazine. Exposure to medetomidine in fentanyl can drive the heart rate as low as 32 beats per minute, cause a sharp drop in blood pressure, and produce deep sedation that outlasts the opioid effect by a considerable margin.

That prolonged sedation matters in first-response situations. Naloxone can restore breathing when fentanyl drives the overdose. But naloxone does nothing against medetomidine’s sedative effect. Health authorities stress that naloxone should still go in first, since fentanyl is almost always present. Responders should focus on breathing, not on whether the person wakes up.

What concerns clinicians most is what happens next. When someone regularly using medetomidine-laced fentanyl stops suddenly, the medetomidine drug threat does not end. Severe withdrawal follows.

A Dangerous Withdrawal Syndrome

Unlike opioid withdrawal, which is deeply unpleasant but rarely fatal in otherwise healthy adults, medetomidine withdrawal can become medically serious fast. The heart races. Blood pressure climbs to dangerous levels. Nausea and vomiting become uncontrollable. Tremors, chest pain, and shifting levels of consciousness add to the picture.

Symptoms can start within hours of the last use, peaking at 18 to 36 hours. Documented complications include non-ST elevation myocardial infarction and posterior reversible encephalopathy syndrome. Both demand intensive care.

Between September 2024 and January 2025, three Philadelphia hospital systems admitted 165 patients for fentanyl withdrawal complicated by severe autonomic dysfunction. Pittsburgh reported similar clusters from October 2024 to March 2025, with many patients needing dexmedetomidine infusions and ICU-level care. In both cities, the rise in these severe withdrawal cases tracked closely with local medetomidine detections.

In May 2024, a Chicago overdose cluster involving medetomidine in fentanyl resulted in at least 16 hospitalisations and one death. Fentanyl appeared in every single medetomidine-positive sample across 12 confirmed, 26 probable, and 140 suspected cases.

Who Needs to Act?

The CDC and ONDCP advisory sets out clear steps for several groups. Clinicians should use heart rate as a key indicator. Bradycardia points to medetomidine intoxication. Tachycardia combined with hypertension suggests withdrawal. Standard hospital rapid drug screens rarely cover medetomidine, so clinicians need to request dedicated testing when prolonged sedation does not respond to naloxone.

Public health teams should use existing syndromic surveillance to catch unusual spikes in overdose or withdrawal presentations early. Coordinating across hospitals, emergency services, and local health departments will help align the response before clusters grow.

For people who use drugs, medetomidine test strips are now available. Chemists at the UNC Street Drug Analysis Lab report they appear highly sensitive, potentially outperforming existing strips for fentanyl or xylazine. Anyone who suspects regular exposure to medetomidine in fentanyl and wants to stop should seek medical support before doing so. Withdrawal can escalate quickly and without warning.

Poison control centres are available to both clinicians and the public at 1-800-222-1222.

A Familiar and Troubling Pattern

The medetomidine drug threat follows a pattern public health experts know well. Each time enforcement successfully disrupts one adulterant, another takes its place. The new one is usually less familiar, harder to test for, and brings unexpected complications.

The data makes the current situation hard to minimise. Wastewater testing found medetomidine every week in at least 14 states between October 2025 and January 2026. Eight of 20 sentinel monitoring sites recorded medetomidine in more than half of all opioid-positive samples during that same window.

The federal advisory signals that this medetomidine drug threat now requires a coordinated answer. That means clinical readiness, stronger laboratory capacity, active harm reduction outreach, and community awareness working together rather than separately.

Source: dbrecoveryresources